---
schema_version: "secwatch.filing_event.v1"
accession: "0001860742-24-000011"
form_type: "8-K"
ticker: "BLCO"
cik: "0001860742"
company_name: "Bausch & Lomb Corp"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:30:21.600748+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb Q2 revenue $1.216B (+17% YoY); GAAP net loss $151M; raises FY2024 guidance

## Summary
- Revenue $1.216B, up 17% reported and 20% constant currency vs Q2 2023.
- GAAP net loss attributable to BLCO $151M; adjusted EPS $0.13 (vs $0.18 a year ago).
- Pharmaceuticals segment revenue surged 60% YoY to $310M, driven by XIIDRA acquisition and MIEBO launch.
- Raised FY2024 revenue guidance to $4.7-4.8B (prev $4.6-4.7B) and adjusted EBITDA to $850-900M.
- Adjusted EBITDA (non-GAAP) $209M, up from $179M in Q2 2023.

## SEC filing metadata
- accession: 0001860742-24-000011
- form_type: 8-K
- ticker: BLCO
- cik: 0001860742
- company_name: Bausch & Lomb Corp
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860742/000186074224000011/0001860742-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860742/000186074224000011/blco-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860742-24-000011
- JSON: https://secwatch.observer/filing/0001860742-24-000011.json
- Plain text: https://secwatch.observer/filing/0001860742-24-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.